Characterisation of structural determinants and molecular mechanisms involved in Stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. by Santavicca, M. et al.
Biochem. J. (1996) 315, 953–958 (Printed in Great Britain) 953
Characterization of structural determinants and molecular mechanisms
involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate
and furin-type convertases
Maria SANTAVICCA*, Agne' s NOEL*, Herbert ANGLIKER, Isabelle STOLL*, Jean-Pierre SEGAIN*, Patrick ANGLARD*,
Michel CHRETIEN, Nabil SEIDAH and Paul BASSET*s
*Institut de Ge! ne! tique et de Biologie Mole! culaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique/Institut National de la Sante! et de la Recherche
Me! dicale U184/Universite! Louis Pasteur, BP 163, 67404 Illkirch Ce! dex, C. U. de Strasbourg, France, Friedrich Miescher-Institut, P. O. Box 2543, CH-4002 Basel,
Switzerland, and Laboratories of Molecular and Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal,
Quebec, H2W 1R7 Canada
Stromelysin-3 (ST3) is a matrix metalloproteinase (MMP) which
has been implicated in cancer progression and in a number of
conditions involving tissue remodelling. In contrast to other
MMPs which are secreted as zymogens requiring extracellular
activation, ST3 is found in the extracellular space as a potentially
active mature form, suggesting that the activation of the ST3
proform differs from that of other MMPs. We show in the
present study that the ST3 proform is not autocatalytically
processed in the presence of 4-aminophenylmercuric acetate
(APMA). By using ST3}ST2 chimeras, we demonstrate that
resistance to APMA is due to properties associated with both the
ST3 pro- and catalytic domains. In agreement with the ob-
servation made by Pei and Weiss [Pei and Weiss (1995) Nature
(London) 375, 244–247], we find that the requirement for
activation of the ST3 proform by the furin convertase is entirely
contained within a stretch of 10 amino acids located at the
INTRODUCTION
Stromelysin-3 (ST3) [1] belongs to the matrix metalloproteinase
(MMP) family, enzymes which are believed to be mediators of
physiological and pathological tissue remodelling processes [2–5].
ST3 is expressed in most invasive human carcinomas ([6] and
references therein), in some precursor lesions [6,7], and in a
number of other conditions including wound healing [8], mam-
mary gland involution [9], cycling endometrium [10], embryonic
development [11] and metamorphosis [12]. As for the other
stromelysins, ST3 has four protein domains, these being an N-
terminal signal peptide followed by a propeptide, a catalytic
domain containing the zinc-binding site, and a C-terminal
haemopexin-like domain [1,13]. However, ST3 differs from the
other stromelysins in that mature forms of human ST3 cannot
cleave any of the major components of the extracellular matrix
[14,15].
With the exception of the recently described membrane-type
MMPs (MT-MMPs) [16,17], all known MMPs are secreted as
soluble zymogens and require activation in the extracellular
space [18,19]. In itro, zymogen activation can be achieved
Abbreviations used: APMA, 4-aminophenylmercuric acetate ; ST3, stromelysin-3 ; h, human; m, mouse; hproST3-hEST2, chimera composed of
the hST3 prodomain in front of the hST2 mature form; hproST3(D10)-hEST2, chimera composed of the hST3 prodomain minus its 10 C-terminal amino
acids in front of the hST2 mature form; (N)ST3-ST2(C), either of these two chimeras ; hproST2-hEST3, chimera composed of the hST2 prodomain in
front of the hST3 mature form; hproST2-(10)hEST3, chimera composed of the hST2 prodomain in front of the hST3 mature form N-terminally extended
with the 10 C-terminal amino acids of the hST3 prodomain; (N)ST2-ST3(C), either of these two chimeras ; MAb, monoclonal antibody; MCF7hST3/9,
a clone of MCF7 cells stably transfected to express a full-length hST3 cDNA; MMP, matrix metalloproteinase ; TGN, trans-Golgi network ; PMA, phorbol
12-myristate 13-acetate ; lmwPE, low-molecular-mass ST3 proform; hmwPE, high-molecular-mass ST3 proform.
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junction between the ST3 pro- and catalytic domains. Furin
cleaves human and mouse ST3 equally well. However, PACE-4,
a furin-like convertase, is much more efficient on the mouse
enzyme, suggesting that ST3 protein determinants other than the
conserved Ala-Arg-Asn-Arg-Gln-Lys-Arg sequence preceding
the furin cleavage site are implicated in PACE-4 action. Finally,
we show that processing of the ST3 proform is inhibited by a
furin inhibitor in human MCF7 breast cancer cells stably
transfected to constitutively express a full-length human ST3
cDNA. Using brefeldin A, we demonstrate that, in these MCF7
cells, the 56 kDa precursor form of ST3 is post-translationally
modified in the cis- or media-Golgi into a 62 kDa proform.
Thereafter, its processing into the 47 kDa mature form occurs in
the trans-Golgi network and is followed by secretion into the
extracellular space.
without prodomain cleavage by agents such as SDS, or by
autocatalytic cleavage of the prodomain in the presence of
organomercurial compounds such as 4-aminophenylmercuric
acetate (APMA). In io, zymogen activation is believed to be
initiated by serine proteinases such as plasmin, or by cell-surface
binding as demonstrated for gelatinase A, both leading to
prodomain removal. However, the predominant human ST3
form detected in culture media conditioned by cells expressing
either recombinant [14] or the endogenous [20] enzyme corres-
ponds to a mature form which has lost the prodomain.
These observations, suggesting that activation of the ST3
proform differs from that of other MMPs, prompted us to
characterize the molecular mechanism implicated in this ac-
tivation. We found that the ST3 proform is not autocatalytically
processed in the presence of APMA. By using ST3}ST2 chimeras,
we demonstrated that the resistance to APMA is due to properties
associated with both the ST3 pro- and catalytic domains. In
agreement with the observation made by Pei and Weiss [21], we
found that the requirement for activation of the ST3 proform by
the furin convertase was entirely contained within a stretch of 10
amino acids located at the junction between the ST3 pro- and
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catalytic domains. Finally, by using human MCF7 breast cancer
cells stably transfected to express a full-length human ST3
cDNA, we showed that intracellular processing of the ST3
zymogen is prevented in the presence of a furin inhibitor. These
findings add support to the concept that ST3 is an MMP with
unique functional properties, and that the intracellular processing
of ST3 by furin is biologically relevant.
EXPERIMENTAL
cDNA constructions
Full-length cDNAs for human (h) [1] and mouse (m) [9] ST3, and
for hST2 [13] were cloned into the pSG5 expression vector [22].
Human furin [23] and PACE-4 [24] cDNAs were cloned into the
pcDNA3 vector (Invitrogen). To generate chimeric proteins in
which the hST2 prodomain was swapped with that of hST3
[(N)ST3-ST2(C)], or in which the hST3 prodomain was swapped
with that of hST2 [(N)ST2-ST3(C)], site-directed mutagenesis
was performed on hST3 and hST2 cDNAs in order to introduce
an XbaI cleavage site at nucleotide positions 256–261 or 286–291
of hST3 cDNA, and 289–294 of hST2 cDNA (nucleotides
numbered from the initiation codon). Since the pSG5 vector
contains an unique XbaI site 5« to the cloning site, XbaI restriction
fragments were generated and exchanged between the two
plasmids containing either the hST3 or the hST2 cDNA. Thus,
the cDNA fragments encoding the 87 [hproST3D(10)] or 97
(hproST3) N-terminal amino acids of hST3 were ligated 5« to the
portion of the cDNA encoding the hST2 mature form (hEST2,
amino acids 99–476), to generate the hproST3(D10)-hEST2 and
hproST3-hEST2 chimeras respectively. Conversely, the cDNA
fragment encoding the 98 N-terminal amino acids of hST2
(hproST2) was ligated 5« to the cDNA portion encoding the
hST3 mature form (hEST3, amino acids 98–488) or an N-
terminally extended hEST3 form [(10)hEST3] (amino acids
88–488), to generate the hproST2-hEST3 and hproST2-
(10)hEST3 chimeras respectively. The introduction of XbaI
cloning sites in the ST3 and ST2 cDNAs having led to modifica-
tions of amino acid sequences, these were corrected by performing
a second site-directed mutagenesis to restore the correct sequence.
Thus, Ser-Arg residues (TCTAGA corresponding to the XbaI
restriction site) were replaced by Ser-Asp (residues 86–87 of
hST3) or Lys-Arg (residues 96–97 of hST3) and Gly-His (residues
97–98 of hST2).
Conditioned media and cell extracts
All cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% (v}v) fetal-calf serum. COS-1 cells
(A.T.C.C. CRL1650) were transiently transfected using the
calcium phosphate precipitation procedure, with 5 lg of each
expression vector (completed to 20 lg with pBluescript DNA)
per dish (10-cm-diam., Falcon) [25]. Conditioned media were
collected after 48 h of incubation in serum-free conditions and
centrifuged at 100000 g for 1 h, in order to eliminate cell debris.
Cleared media were concentrated 100-fold by 80% ammonium
sulphate precipitation and then dialysed against 20 mM
Tris}HCl, pH 7.4, 100 mM NaCl, 5 mM CaCl
#





prior to analyses. MCF7hST3}9 cells corre-
sponding to human MCF7 breast cancer cells stably transfected
with a pCMV expression vector containing a full-length hST3
cDNA (A. Noe$ l, unpublished work) were cultured to subcon-
fluence in 1-cm-diam. dishes (Falcon) in the presence of 10%
(v}v) fetal-calf serum. Cells were then cultured in serum-free
medium supplemented with the furin inhibitor Dec-Arg-Val-
Lys-Arg-CH
#
Cl [26] at concentrations varying from 0 to 100 lM.
After 24 h, conditioned media were centrifuged at 10000 g for
30 min to eliminate cell debris and used directly for subsequent
analyses. Cells were washed with cold PBS and then lysed in
100 ll of the same buffer supplemented with 1% Nonidet P40
and 10 mM EDTA. For brefeldin A (Sigma, B-7651) treatment,
subconfluent MCF7 cells were preincubated with 0.5 lg}ml
brefeldin A for 1 h in serum-free medium, washed with serum-
free medium and then incubated in fresh serum-free medium
with 0.5 lg}ml brefeldin A for 0 to 24 h, before harvesting cells
as described above.
Protein analyses
Proteins in conditioned media and cell extracts were separated by
SDS}12%-PAGE under reducing conditions. After Western
blotting, proteins were detected by using three distinct antibodies :
monoclonal antibody (MAb) 5ST-4C10 directed against the
hST3 catalytic domain [27] ; MAb 6ST-1E11 against the ST3
prodomain was obtained by immunizing mice with a synthetic
peptide corresponding to amino acids 41–60 of hST3; R654
polyclonal antibody directed against the mature form of hST2
was obtained by immunizing rabbits with recombinant hEST2
expressed in Escherichia coli as an N-terminal six-histidine fusion
protein and recovered from bacterial inclusion bodies, according
to the procedure described by Santavicca et al. [27]. Western
blots were revealed by enhanced chemiluminescence (ECL,
Amersham) using peroxidase-coupled anti-(mouse IgG) or anti-
(rabbit IgG) (Jackson).
RNA analyses
Subconfluent human diploid HFL1 fibroblasts (A.T.C.C.
CCL153) were cultured in serum-free medium supplemented or
not with 10 ng}ml of phorbol 12-myristate 13-acetate (PMA).
After 24 h of culture, RNAs extracted according to the protocol
ofChomczynski and Sacchi [28] were separated on formaldehyde-
containing 1% agarose gels prior to transfer on to Hybond N
membranes (Amersham). Filter hybridizations were performed
using a hST3 cDNA probe [7], and a 420 bp human furin cDNA
fragment (nucleotides 170–590) generated by the PCR. Both
probes were labelled with [$#P]dCTP by random-primed syn-
thesis. Filters were reprobed with the $#P-labelled 36B4 cDNA
[29] to check for loading and transfer.
RESULTS
APMA-induced processing of ST2, ST3 and (N)ST3-ST2(C)
chimeras
Media conditioned by COS-1 cells transiently transfected with
pSG5 plasmids encoding hST3 or hST2 were incubated in the
presence of 1 mM APMA. After incubation at 37 °C for 0 to
16 h, conditioned media were analysed by Western blotting using
MAb 5ST-4C10 directed against the hST3 catalytic domain, and
using polyclonal antibody R654 directed against the mature
form of hST2. In the absence of APMA treatment, two major
protein species were detected both for hST3 and hST2, at the
expected molecular masses for zymogens and mature forms
(Figures 1A and 1B, lanes 1). After 16 h of APMA incubation,
the hST3 pattern remained unchanged (Figure 1A, lane 2), while
the hST2 proform was entirely converted into lower-molecular-
mass forms (Figure 1B, lane 3).
Since molecular perturbation of the zymogen has been shown
to initiate the activation of MMP proforms by APMA [30], we
tested whether the unusual structure of the ST3 prodomain
played a role in the inability of the ST3 proform to be processed
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Figure 1 Western blot analysis of ST3 and ST2 proforms, and (N)ST3-
ST2(C) chimeras treated with APMA
(A) Media conditioned by COS-1 cells transiently transfected with an expression vector encoding
the hST3 proform were concentrated by ammonium sulphate precipitation and aliquots
containing 20 lg of protein were incubated at 37 °C with 1 mM APMA for the indicated times.
After SDS/PAGE and Western blotting, hST3 was detected using MAb 5ST-4C10 directed
against the hST3 catalytic domain. (B) Media conditioned by COS-1 cells transiently transfected
with appropriate expression vectors encoding the hST2 proform or (N)ST3-ST2(C) chimeras
were collected as described in (A), and incubated at 37 °C with 1 mM APMA for the indicated
times, before analysis by Western blotting using polyclonal antibody R654 directed against the
hST2 mature form. In the (N)ST3-ST2(C) chimeras, the prodomain of hST2 was swapped with
that of hST3 without [hproST3(D10)-hEST2] or with (hproST3-hEST2) its 10 C-terminal amino
acids (see also the Experimental section). In (A) and (B), PE and E indicate zymogens and
mature forms respectively.
Figure 2 Comparison of ST3 and ST2 amino acid sequences at the
junctions of pro- and catalytic domains
Amino acids are represented using the one-letter code. The conserved amino acids surrounding
the conserved MMP prodomain cysteine residue, and the 10 extra amino acids characteristic
of the ST3 prodomain, are boxed. The conserved cysteine and the residues corresponding to
the furin recognition site [32] within these 10 amino acids are in bold letters, and the
corresponding cleavage site is marked by an arrow.
in the presence of APMA. Apart from the characteristic
‘Pro}Leu-Arg-Cys-Gly-Val-Pro-Asp’ sequence, the ST3 pro-
domain does not exhibit significant amino acid sequence simi-
larities with other MMPs [1], and it is further characterized by
the presence of 10 extra amino acids located at its junction with
the catalytic domain (Figure 2). (N)ST3-ST2(C) chimeras,
having the hST3 prodomain with (hproST3-hEST2) or without
[hproST3(D10)-hEST2] the 10 extra amino acids characteristic of
ST3 in front of the mature hST2 form, were transiently expressed
in COS-1 cells and tested for autoactivation in the presence of
APMA for 0–16 h. While the hST2 zymogen was completely
converted into the corresponding mature form within 3 h of
APMA treatment (Figure 1B, lane 2), full processing of the
hproST3(D10)-hEST2 chimera required 16 h (Figure 1B, lanes
4–6) and processing of the hproST3-hEST2 chimera was in-
complete even after 16 h of APMA incubation (Figure 1B, lanes
7–9). Importantly, these (N)ST3-ST2(C) chimeras were found to
have retained enzymic activities against casein as tested by
zymography (results not shown).
Figure 3 Western blot analysis of ST3 and ST2 proforms and (N)ST3-
ST2(C) chimeras processed by furin or PACE-4
COS-1 cells were transiently co-transfected with expression vectors for furin or PACE-4, and
vectors for hST3 or mST3 or hST2 or the indicated (N)ST3-ST2(C) chimeras (see the legend
of Figure 1 for definition). Conditioned media were collected and analysed as described in the
legend of Figure 1. PE and E indicate zymogens and mature forms respectively.
Convertase-dependent processing of ST3, and (N)ST3-ST2(C) and
(N)ST2-ST3(C) chimeras
These results indicated that the 10 extra amino acids characteristic
of ST3 at the junction between the pro- and catalytic domains
(Figure 2) were in part responsible for the inability of the ST3
proform to autoactivate in the presence of APMA. Interestingly,
these amino acids have been recently shown to contain a
functional furin cleavage site [21]. Consistently, when expression
vectors encoding either hST3 or mST3 and human furin were co-
transfected into COS-1 cells (containing only low levels of
endogenous furin; [31]), the ST3 proform was entirely con-
verted into lower-molecular-mass forms, these corresponding
to the putative ST3 mature form and to another species of about
28 kDa (Figure 3, lanes 1, 2, 4 and 5). Furthermore, while the
hST2 proform and the hproST3(D10)-hEST2 chimera were not
processed by furin (Figure 3, lanes 7, 8, 10 and 11), the hproST3-
hEST2 chimera was processed by furin (Figure 3, lanes 13 and
14). These results indicated that the sole requirement for furin
action was located within the Gly-Leu-Ser-Ala-Arg-Asn-Arg-
Gln-Lys-Arg sequence corresponding to the C-terminal portion
of the hST3 prodomain. Accordingly, the replacement of the
hST3 prodomain by that of hST2 led to an (N)ST2-ST3(C)
chimera (hproST2-hEST3) which could not be activated by furin
(Figure 4, lanes 1 and 2), while the hproST2-(10)hEST3 chimera,
in which the Gly-Leu-Ser-Ala-Arg-Asn-Arg-Gln-Lys-Arg sequ-
ence was inserted, was fully processed (Figure 4, lanes 3 and 4).
However, it appears that protein determinants other than the
Arg-Asn-Arg-Gln-Lys-Arg furin recognition site [32] found in
the prodomains of both hST3 and mST3 (Figure 2), play a role
in the ability of the furin-like convertase PACE-4 to activate the
ST3 proform. Indeed, while PACE-4 was found to process the
mST3 proform almost as efficiently as furin (Figure 3, lanes 5
and 6), PACE-4 was much less active on the human enzyme
(Figure 3, lane 3) and on the hproST3-hEST2 chimera (Figure 3,
lane 15).
Inhibition of ST3 processing by a furin inhibitor
MCF7hST3}9 human breast cancer cells stably transfected to
constitutively express a full-length hST3 cDNA (A. Noe$ l, un-
published work) were cultured in the presence or absence of the
furin inhibitor Dec-Arg-Val-Lys-Arg-CH
#
Cl [26], and ST3 ex-
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Figure 4 Western blot analysis of (N)ST2-ST3(C) chimeras processed by
furin
COS-1 cells were transiently co-transfected with expression vectors for furin and for the
indicated (N)ST2-ST3(C) chimeras in which the hST3 prodomain was swapped with the hST2
prodomain (hproST2-hEST3) or with the hST2 prodomain C-terminally extended with the 10 C-
terminal amino acids of the hST3 prodomain [hproST2-(10)hEST3] (see also the Experimental
section). Conditioned media were collected and analysed using polyclonal antibody R654
directed against the hST2 mature form, as described in the legend of Figure 1.
Figure 5 Western blot analysis of ST3 expression in MCF7hST3/9 cells
treated with a synthetic furin inhibitor
MCF7hST3/9 cells stably transfected with an expression vector encoding a full-length hST3
cDNA were cultured in serum-free conditions for 24 h in the presence of increasing
concentrations (0 to 100 lM) of the synthetic furin inhibitor Dec-Arg-Val-Lys-Arg-CH2Cl. Cell
extracts and conditioned media were analysed by Western blotting using MAb 5ST-4C10
directed against the hST3 catalytic domain (A) and MAb 6ST-1E11 directed against the hST3
prodomain (B). Abbreviations : hmwPE and lmwPE, high- and low-molecular-mass hST3
proforms respectively ; E, hST3 mature form.
pression patterns were evaluated by Western blot analysis. In the
absence of the inhibitor, we could detect a major protein species
at an average molecular mass of 56 kDa (lmwPE) in
MCF7hST3}9 cell extracts. This form corresponded to the ST3
proform since it was recognized by both MAb 5ST-4C10, raised
against the ST3 catalytic domain (Figure 5A, lane 1), and MAb
6ST-1E11, directed against the hST3 prodomain (Figure 5B, lane
1). A minor protein species at an average molecular mass of
47 kDa was specifically detected by MAb 5ST-4C10, and it
corresponded to the mature ST3 form. However, in media
conditioned by MCF7hST3}9 cells, only the 47 kDa mature ST3
form could be detected (Figures 5A and 5B, lanes 7). By
incubating MCF7 hST3}9 cells with increasing concentrations of
furin inhibitor for 24 h, we observed the appearance in cell
Figure 6 Western blot analysis of ST3 expression in MCF7hST3/9 cells
treated with brefeldin A
MCF7hST3/9 cells stably transfected with an expression vector encoding a full-length hST3
cDNA were cultured in serum-free conditions in the presence of 0.5 lg/ml brefeldin A for the
indicated times. Cell extracts were analysed by Western blotting using MAb 5ST-4C10 directed
against the hST3 catalytic domain. Abbreviations : hmwPE and lmwPE, high- and low-molecular-
mass ST3 proforms respectively ; E, hST3 mature form.
extracts of a second higher-molecular-mass ST3 proform
(hmwPE), at about 62 kDa (Figures 5A and 5B, lanes 2–6).
Concomitantly in media conditioned by these cells, we also
detected the 62 kDa ST3 proform, while the amount of the
47 kDa mature ST3 form was found to progressively decrease
(Figures 5A and 5B, lanes 8–12).
Taken together, these results suggested that the hmwPE protein
species was a post-translationally modified ST3 proform derived
from the lmwPE form, and that it corresponded to the ST3
proform cleaved by furin in the trans-Golgi network (TGN) [33].
To evaluate this possibility further, we disrupted the transport of
proteins from the endoplasmic reticulum to the Golgi complex
by using brefeldin A, a fungal metabolite which is known to
functionally isolate the TGN from the rest of the Golgi complex
[33–35]. When MCF7hST3}9 cells were incubated in the presence
of 0.5 lg}ml brefeldin A, increasing amounts of the hmwPE
form were detected in cell extracts, while the levels of the lmwPE
remained stable (Figure 6). This indicates that the ST3 proform
(lmwPE) is post-translationally modified in the cis- or media-
Golgi before its processing in the TGN to the mature form.
Comparative expression of furin and ST3 RNAs in human
fibroblasts
Since the ST3 gene is specifically expressed in fibroblastic cells of
human carcinomas [6], we tested whether the ST3 and furin genes
could be co-ordinately expressed in human HFL1 fibroblasts
known to express ST3 and other MMPs implicated in cancer
progression [1,36]. While the levels of ST3 RNA were found to
progressively increase in HFL1 cells treated with PMA
(10 ng}ml), furin RNA was found to be constitutively expressed
in these cells, and its expression level was not affected by PMA
addition (Figure 7).
DISCUSSION
In media conditioned by cells expressing the endogenous ST3
gene [20] or stably transfected ST3 cDNAs constructs [14,15],
ST3 is detected in a form which has lost theN-terminal propeptide
rather than being detected in a proform. These observations
contrast with those made for other MMPs which are secreted as
zymogens, requiring activation in the extracellular space [5,18,19].
The present study was undertaken to determine how this unusual
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PMA(h)
Figure 7 Northern blot analysis of ST3 and furin RNAs in HFL1 fibroblasts
HFL1 cells cultured in serum-free conditions were incubated in the presence of 10 ng/ml PMA
for the indicated times. Total RNA (8 lg of RNA per lane) was separated by electrophoresis
and transferred to a nylon filter which was successively hybridized with 32P-labelled cDNA
probes specific for hST3 and furin. In order to check loading and transfer, the filter was re-
rehybridized with a 36B4 cDNA.
expression pattern could be related to an activation mechanism
for the ST3 zymogen which differs from those reported for other
MMPs.
The latent forms of MMPs can be activated by a variety of
means, collectively known as the ‘cysteine-switch mechanism’
[37]. This involves disruption of the bond existing between the
conserved cysteine of the MMP prodomain and the zinc atom of
the catalytic site. The ‘cysteine switch’ is regarded as requiring
two steps, in which the initial destabilization of the prodomain is
usually followed by its autoproteolytic cleavage or its removal
with the help of another MMP ([30,38] and references therein).
In itro, the proforms of all secreted MMPs so far characterized
have been found to be readily activated by APMA, which is
believed to unlock the active centre of the zymogen, and thus
permit the subsequent autocatalytic cleavage of the propeptide.
In the case of ST3, however, we observed that the ST3 zymogen
was not processed to its corresponding mature form in the
presence of APMA. We previously proposed that this was due to
the unusual structure of the ST3 prodomain [39]. Indeed, the ST3
prodomain does not exhibit significant homologies with the
corresponding domains of most other MMPs, apart from the
Pro}Leu-Arg-Cys-Gly-Val-Pro-Asp sequence [1,9]. Consistently,
in the present study using (N)ST3-ST2(C) chimeras we found
that hST3 resistance to APMA activation could be transferred to
hST2 by swapping the hST2 prodomain with that of hST3.
However, a small amount of the hproST3-hEST2 chimera, but
not of the hST3 zymogen, could be converted into lower-
molecular-mass species after prolonged activation (16 h) with
APMA, suggesting that functional characteristics of the ST3
catalytic domain also contribute to this APMA resistance. In this
regard, we note that human, and to a certain extent mouse, ST3
are characterized by both their limited spectra and low levels of
activity [14,15,39]. Accordingly, we observed that the (N)ST2-
ST3(C) chimera in which the hST3 prodomain was swapped with
that of hST2 could not be activated in the presence of APMA
(results not shown).
Altogether, these findings indicate that the activation mech-
anism for the ST3 zymogen differs from those of other MMPs,
and that at least part of this difference is due to the particular
structure of the ST3 prodomain. In addition to its weak homology
with corresponding domains of other MMPs, the ST3 prodomain
is characterized by the presence of 10 extra amino acids at its
junction with the catalytic domain [1,9]. Comparable stretches of
amino acids have been described in the membrane-type MMPs
[16,17], and have been proposed to play a role in zymogen
activation because they each contain a potential cleavage site for
furin or furin-type convertases [16]. In agreement with this
hypothesis and with the recent finding of Pei and Weiss [21], we
found that the hST3 proform was processed to its mature form
by furin when cDNAs encoding both proteinases were transiently
co-transfected into COS-1 cells. By using (N)ST3-ST2(C) and
(N)ST2-ST3(C) chimeras, we demonstrated that the information
necessary to allow processing of the hST3 proform by furin was
entirely contained within the 10 extra amino acids characteristic
of the ST3 prodomain. The mST3 proform was also found to be
processed by furin. However, while the hST3 proform was much
less processed by PACE-4, another convertase of the furin-type
[31], the mouse enzyme, was processed equally well by PACE-4
and furin. This observation suggests that ST3 protein deter-
minants other than the conserved Ala-Arg-Asn-Arg-Gln-Lys-
Arg sequence containing the furin recognition site (Figure 2) may
play roles in the capacity of furin-type convertases to cleave the
ST3 prodomain.
To evaluate further the possibility that furin or furin-type
convertases are the biologically relevant activators of the ST3
proform, we examined ST3 expression in human MCF7 breast
cancer cells which had been stably transfected with a full-length
hST3 cDNA. In medium conditioned by these cells, the major
protein species which was immunodetected corresponded to the
47 kDa mature form of hST3. In cell extracts, however, a 56 kDa
proform was mainly found, with only low levels of mature form.
In the presence of increasing concentrations of the furin inhibitor
Dec-Arg-Val-Lys-Arg-CH
#
Cl [26], the 47 kDa form progressively
disappeared from conditioned media, while the predominant
secreted ST3 form was found to correspond to a 62 kDa proform.
These observations suggest that ST3 is first translated into a
precursor form of 56 kDa and then post-translationally modified
into a 62 kDa proform which is translocated to the cell surface
through the TGN, where it is proteolytically processed and
finally secreted as a 47 kDa mature form. When MCF7 cells were
cultured in the presence of brefeldin A, the 62 kDa proform
accumulated intracellularly to high levels. This indicates that the
post-translational modification of the ST3 proform occurs early
after ST3 protein synthesis, probably in the endoplasmic reti-
culum and}or the cis- and media-Golgi compartments, while its
processing by furin into a mature form occurs in the TGN [35].
Thus, furin appears to be required for ST3 zymogen activation,
although its ubiquitous tissue expression [31] and its constitutive
expression in fibroblasts known to express the ST3 gene under
various stimuli (the present study), suggest that the expression
level of furin itself does not play a critical role in the regulation
of the amount of secreted mature ST3 form.
The secretion of ST3 as a potentially active molecule, in
contrast to other MMPs which are secreted as proforms requiring
activation in the extracellular space, has important implications.
This suggests that ST3 activity does not need to be as tightly
controlled as other secreted proteinases, which can be explained
if ST3 has limited proteolytic activity toward a precise substrate,
or if it has functions other than proteolysis. Both possibilities are
compatiblewith the unusual enzymic properties of ST3previously
described [14,15,39]. Alternatively, ST3 might acquire strong
and}or broad proteolytic properties only after interaction with
another protein whose expression would be tightly controlled.
Finally, it cannot be presently excluded that ST3 may exert its
proteolytic activity on a substrate present in the TGN, since we
could detect the presence of the ST3 mature form in cellular
extracts of MCF7 cells stably transfected with the hST3 cDNA.
958 M. Santavicca and others
In this case, the ST3 mature form could be secreted together with
its already processed substrate, and immediately inhibited by the
tissue inhibitors of MMPs (TIMPs) once in the extracellular
space.
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